Johnson & Johnson

(NYSE:JNJ)

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

$147.36 0.44 (0.30%)

Quote Date: Jan 19, 4:16PM EST

Data delayed 15 minutes
Currency in USD

JNJ News

    Texas jury returns $247M verdict against J&J in defective hip implants case


    A federal court jury in Texas returned a $247M verdict on behalf of six people who suffered serious medical complications caused by the defective metal-on-metal hip implants made by Johnson & Johnson and its subsidiary DePuy Orthopaedics Inc. The one-man, seven-woman jury deliberated for 14 hours before reaching its verdict, which includes more than $78M in compensatory damages for the six plaintiffs and more than $168M in punitive damages assessed against Johnson & Johnson and DePuy. The verdict, delivered November 16, 2017, follows claims filed by New York residents Ramon Alicea, Uriel Barzel, Karen Kirschner, Hazel Miura, Michael Stevens, and Eugene Stevens who received DePuy's Pinnacle Acetabular Cup System hip implant. The plaintiffs alleged that the devices had unreasonably high failure rates resulting in severe pain and inflammation, bone erosion, tissue loss and other problems. The victims further claimed that DePuy officials knew about the dangers of the Pinnacle hip implants but failed to warn doctors or patients. The trial was the fourth "bellwether" in the multidistrict litigation consolidating more than 9,000 similar lawsuits nationwide. Bellwether trials are set to establish evidence and evaluate witness testimony that is representative of the issues involved in mass litigation. Two previous trials involving plaintiffs from California and Texas resulted in verdicts of $502M and $1.04B.

    JNJ11/16 14:25 EDT

    Johnson & Johnson not liable for woman's asbestos illness, Law360 reports


    A California Jury ruled in favor of Johnson & Johnson and its talc supplier Imerys Talc America rejecting plaintiffs' allegations that J&J sold talcum powder containing asbestos which resulted in a woman's terminal mesothelioma, Law360 reports, citing the ruling. The jury found no evidence that J&J negligently designed or sold its talc, that the talc failed to perform as safely, that the talc was defective, or that J&J failed to warn of any potential risks, "known or knowable based on general scientific knowledge at time of sale." [Reference Link]:Link

    JNJ11/16 13:43 EDT

    J&J beats LA suit claiming talc powder caused cancer, Bloomberg reports

    JNJ11/16 13:33 EDT

    Jefferies names Roche new top global pick in Pharmaceuticals


    Jefferies analyst Jeffrey Holford names Roche (RHHBY) his new "Top Pick Globally" in Pharmaceuticals following the strong share performance of his previous top pick for 2017, AbbVie (ABBV). The analyst believes the company's growth outlook is better than many investors think. Roche is nearing sentiment lows and investors "need to look hard at the replacement power" offered by assets Tecentriq, Ocrevus, Gazyva, ACE910 and Perjeta, Holford tells investors in a research note. Following Roche, the analyst has the highest conviction on Novartis (NVS), Bayer (BAYRY), AbbVie, Johnson & Johnson (JNJ), Zoetis (ZTS) and Eli Lilly (LLY). His least preferred stocks in Pharmaceuticals are Merck (MRK), Novo Nordisk (NVO) and AstraZeneca (AZN).

    RHHBY;ABBV;NVS;BAYRY;JNJ;ZTS;LLY;MRK;NVO;AZN11/16 05:33 EDT

    J&J's Janssen drops suit against Samsung Bioepis' RA drug, Reuters reports


    Janssen Biotech, a unit of Johnson & Johnson (JNJ), has voluntarily dropped its lawsuit seeking to block a copy of its Remicade drug for rheumatoid arthritis produced by Samsung Bioepis (SSNLF, BIIB) from being sold in the U.S., Reuters reports. Janssen filed the suit in May to probe whether Samsung Bioepis violated its manufacturing process patents. [Reference Link]:Link

    JNJ;SSNLF;BIIB11/14 06:20 EDT

    Zymeworks to hold a pharmaceutical update conference call


    Management discusses the license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop Azymetric and EFFECT platforms on a conference call to be held on November 13 at 8:30 am. [Webcast Link]:Link

    JNJ;ZYME;ZYME11/13 06:57 EDT

    J&J, Gilead settle suit against Mylan over Complera patents, Bloomberg says

    JNJ;GILD;MYL11/10 12:53 EDT

    Unusually active option classes on open November 10th


    Unusual total active option classes on open include: Diamond ETF (DIA), Disney (DIS), J C Penney (JCP), Johnson & Johnson (JNJ), and Kroger (KR).

    DIA;DIS;JCP;JNJ;KR11/10 09:40 EDT

    Carlyle exploring sale, IPO for Ortho-Clinical Diagnostics, Reuters reports


    Carlyle Group (CG) is considering a sale or IPO for U.S. diagnostics company Ortho-Clinical Diagnostics, Reuters reports, citing people familiar with the matter. Ortho-Clinical Diagnostics, which Carlyle acquired from Johnson & Johnson (JNJ) in 2014 for $4B, could be valued at more than $7B, including debt, the people say. [Reference Link]:Link

    CG;JNJ11/10 06:18 EDT

    Protagonist Therapeutics initiates Phase 1 trial of PTG-200


    Protagonist Therapeutics (PTGX) announced the initiation of dosing in a Phase I healthy volunteer study of PTG-200, a potential first-in-class, gastrointestinal-restricted, oral peptide interleukin-23 receptor antagonist. PTG-200 works by blocking the IL-23 pathway, a mechanism that has been targeted by currently marketed injectable antibody treatments for inflammatory bowel disease and other autoimmune conditions. The Phase 1 study, which is being conducted in Australia, is a randomized, double-blind, placebo-controlled, single and multiple dose-escalation trial in approximately eighty healthy volunteers. The study will be conducted in three parts: single-ascending doses of PTG-200; multiple ascending doses; and a single dose cross-over, comparing tablet to capsule formulations of PTG-200. Primary endpoints for the study are safety and tolerability of PTG-200. Secondary endpoints include the identification of the maximally tolerated dose and evaluation of pharmacokinetic and pharmacodynamic parameters. Protagonist is developing PTG-200 in collaboration with Janssen Biotech (JNJ), which has licensed the worldwide rights to PTG-200 for all indications including IBD.

    PTGX;JNJ11/9 08:14 EDT

    Halozyme announces Janssen Biotech began Phase 3 clinical trials for Darzalex


    Halozyme Therapeutics (HALO) announced that Janssen Biotech has initiated the first of three planned Phase 3 clinical trials evaluating a subcutaneous, or SC, delivery of Darzalex with Halozyme's proprietary ENHANZE technology. The initial Phase 3 study is in amyloidosis patients, with additional Phase 3 studies in multiple myeloma and smoldering myeloma patients planned for near-term initiation. The Phase 3 study follows a Phase 1b clinical trial that demonstrated the safety, pharmacokinetics and anti-tumor activity of the subcutaneous formulation in relapsed or refractory multiple myeloma patients. Halozyme will receive a $15M milestone payment from Janssen following dosing of the third patient in a Phase 3 trial. Janssen Biotech is wholly owned subsidiary of Johnson and Johnson

    HALO;JNJ10/31 08:40 EDT

    Geron granted Fast Track designation to imetelstat by FDA


    Geron (GERN) announced that the FDA has granted Fast Track designation to imetelstat for the potential treatment of adult patients with transfusion-dependent anemia due to Low or Intermediate-1 risk myelodysplastic syndromes, or MDS, who are non-del(5q) and who are refractory or resistant to treatment with an erythropoiesis stimulating agent, or ESA. Imetelstat is a telomerase inhibitor initially developed by Geron and exclusively licensed to Janssen Biotech, (JNJ) on a worldwide basis. Janssen sponsored the application for Fast Track designation utilizing preliminary data from IMerge, the ongoing clinical trial being conducted by Janssen in lower risk MDS.

    GERN;JNJ10/31 07:41 EDT

    Pacira downgraded to Sell from Neutral at Janney Capital


    Janney Capital analyst Ken Trbovich downgraded Pacira Pharmaceuticals (PCRX) to Sell and cut his price target for the shares to $27 from $36. Symphony Health data shows no signs Exparel growth is taking hold, Trbovich tells investors in a research note. The analyst sees no evidence of a benefit from Johnson & Johnson's (JNJ) Depuy Synthes sales force and believes Q3 estimates are too high. Deterioration in Exparel growth is likely to lead management to cut their full outlook when reporting Q3, Trbovich writes. He sees 20% downside from current share levels. Pacira closed yesterday down 5% to $31.85.

    PCRX;JNJ10/26 07:22 EDT

    Pfizer to begin consumer health sale in November, Reuters reports


    Pfizer (PFE) is expecting to begin an auction process for its consumer healthcare business, which could potentially bring in over $15B, Reuters reports, citing sources close to the matter. Possible suitors include GlaxoSmithKline (GSK), Reckitt Benckiser (RBGLY), Procter & Gamble (PG), Sanofi (SNY), Johnson & Johnson (JNJ), and Nestle (NSRGY) and the drugmaker has already held preliminary discussions with interested parties including Reckitt. [Reference Link]:Link

    PFE;GSK;RBGLY;PG;SNY;JNJ;NSRGY10/26 06:28 EDT

    Janssen's SYMTUZA shows 'positive outcome' in AMBER study


    Janssen's new once-daily, single tablet combination therapy SYMTUZA alafenamide has shown to be both highly effective and well-tolerated in treating antiretroviral-naive HIV-1 patients through 48 weeks in the pivotal phase 3 AMBER study.1 The results of this study will be presented on 27 October 2017 at the 16th European AIDS Conference in Milan, Italy. Findings from the study demonstrated that the single tablet regimen D/C/F/TAF provided effective and durable viral suppression, meaning most patients achieved an undetectable viral load, whilst offering the high genetic barrier to resistance of darunavir, for ART-naive HIV-1-infected patients. AMBER is a Phase 3 randomised double-blind non-inferiority international study designed to assess the efficacy and safety of D/C/F/TAF versus the control in HIV-1 positive treatment-naive adult patients over 48 weeks. The control comprised two separate medications - a tablet of darunavir/ cobicistat plus a tablet of emtricitabine/ tenofovir disoproxil fumarate. The primary endpoint was non-inferiority of the STR versus the control regarding the proportion of patients with a viral load of less than 50 copies per mL at 48 weeks. Reducing their viral load to an undetectable level is a key treatment goal for HIV patients, enabling their immune system to strengthen and leading to improved quality of life. The single tablet D/C/F/TAF demonstrated durable non-inferiority versus the control group over 48 weeks and also produced low virologic failure rates. The high efficacy results were consistent across different subgroups of patients. No treatment-emergent mutations related to darunavir, primary protease inhibitors or tenofovir were observed. The STR showed improved bone and renal safety laboratory parameters, along with similar safety versus control through 48 weeks, in terms of rates of discontinuations due to adverse events , of Grade 3-4 AEs and of serious AEs. D/C/F/TAF also demonstrated a similar total cholesterol/HDL cholesterol ratio, with limited lipid changes. D/C/F/TAF safety and efficacy were also demonstrated in the open label Phase 3 48-week EMERALD study, a switch trial amongst virologically suppressed ART experienced patients.

    JNJ10/25 08:02 EDT

    Unusually active option classes on open October 24th


    Unusual total active option classes on open include: AGNC Investment Corp. (AGNC), Corning (GLW), McDonald's (MCD), L Brands (LB), Johnson & Johnson (JNJ), Seagate (STX), and Celgene (CELG).

    AGNC;GLW;MCD;LB;JNJ;STX;CELG10/24 09:40 EDT

    Johnson & Johnson management to meet with MKM Partners


    Meeting to be held in New York at 9 am on October 27 hosted by MKM Partners.

    JNJ10/23 11:13 EDT

    Johnson & Johnson wins reversal of $417M talc verdict, Bloomberg reports


    A court has reversed a $417M jury verdict against Johnson & Johnson after a judge agreed the company was not responsible for warning a woman, who has since died, that its Baby Powder could cause ovarian cancer, Bloomberg reports, citing the ruling. The decision follows an earlier ruling that voided a $72M talc-powder verdict against J&J, which has denied there's an increased cancer risk from using its talc products. [Reference Link]:Link

    JNJ10/23 09:33 EDT

    World Congress to hold a summit


    5th Annual Patient Advocacy Summit is being held in Arlington, VA on October 23-24.

    MRK;TKPYY;PFE;AGN;ONCE;PODD;ACHN;SNY;ABEO;JNJ;AZN;SHPG;GSK;BMY;SCMP;PCRX;TKPYY;PFE;AGN;ONCE;PODD;ACHN;SNY;ABEO;JNJ;AZN;SHPG;GSK;BMY;SCMP;PCRX10/23 07:34 EDT

    Johnson & Johnson price target raised to $154 from $147 at Credit Suisse


    Credit Suisse analyst Vamil Divan raised his price target for Johnson & Johnson to $154 from $147 following Q3 results. The analyst reiterates an Outperform rating on the shares.

    JNJ10/19 09:35 EDT

    Arcturus, Johnson & Johnson announce strategic collaboration for RNA medicines


    Arcturus Therapeutics announced that it has entered into a research collaboration and worldwide license agreement with Janssen Pharmaceuticals, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ). The two companies will work together to develop and commercialize nucleic acid-based drug products for the treatment of Hepatitis B, using Arcturus' UNA Oligomer chemistry and LUNAR lipid-mediated delivery platform. The agreement also includes an option to expand into other infectious and respiratory diseases. The deal was facilitated by the Johnson & Johnson Innovation center, in California.Under the agreement, Arcturus will receive an upfront cash payment, R&D support, and pre-clinical, development, and sales milestone payments, as well as royalty payments on any future licensed product sales. Janssen will assume responsibility for development costs and all commercialization costs associated with the program. On September 27, Arcturus and Alcobra (ADHD) entered into an agreement and plan of merger and reorganization pursuant to which a wholly-owned subsidiary of Alcobra will merge with and into Arcturus, with Arcturus becoming a wholly-owned subsidiary of Alcobra and the surviving corporation of the merger, and the holders of Arcturus outstanding capital stock immediately prior to the merger will receive ordinary shares representing approximately 60% of the outstanding shares of Alcobra.

    JNJ;ADHD10/19 07:15 EDT

    Arcturus, Johnson & Johnson announce strategic collaboration for RNA medicines


    Arcturus Therapeutics announced that it has entered into a research collaboration and worldwide license agreement with Janssen Pharmaceuticals, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ). The two companies will work together to develop and commercialize nucleic acid-based drug products for the treatment of Hepatitis B, using Arcturus' UNA Oligomer chemistry and LUNAR lipid-mediated delivery platform. The agreement also includes an option to expand into other infectious and respiratory diseases. The deal was facilitated by the Johnson & Johnson Innovation center, in California.Under the agreement, Arcturus will receive an upfront cash payment, R&D support, and pre-clinical, development, and sales milestone payments, as well as royalty payments on any future licensed product sales. Janssen will assume responsibility for development costs and all commercialization costs associated with the program. On September 27, Arcturus and Alcobra (ADHD) entered into an agreement and plan of merger and reorganization pursuant to which a wholly-owned subsidiary of Alcobra will merge with and into Arcturus, with Arcturus becoming a wholly-owned subsidiary of Alcobra and the surviving corporation of the merger, and the holders of Arcturus outstanding capital stock immediately prior to the merger will receive ordinary shares representing approximately 60% of the outstanding shares of Alcobra.

    JNJ;ADHD10/19 07:12 EDT

    On The Fly: What to watch in Intuitive Surgical earnings report


    Intuitive Surgical (ISRG) is scheduled to report results of its third fiscal quarter after the market close on October 19, with a conference call scheduled for 4:30 pm EDT. What to watch for 1. PROCEDURAL GROWTH: Along with its second quarter report, Intuitive Surgical specified its much-watched procedural growth view for its daVinci system to 14%-15% from 12%-14% for 2017. On its Q2 conference call, the company said it anticipates contributions from China and Japan to temper. Intuitive added that the average selling price will vary quarter-to-quarter, adding that it anticipates the system selling price to continue to trend gradually lower in the back half of 2017. The company raised its FY17 pro-forma gross profit margin to 71%-75% of net revenue from 69%-71%. 2. TRANSENTERIX RIVALRY: Shortly after its last earnings report, back in late July, Barclays analyst Matthew Taylor said one of the only reasons for concern is the potential for competition. Just last week, a smaller rival in the robotic surgery space, TransEnterix (TRXC) got FDA clearance for its Senhance System, a new robotically-assisted surgical device that can help facilitate minimally invasive surgery. Shares of Intuitive dipped on the news. Citi analyst Amit Hazan came to Intuitive's rescue in a research note out the next day. Hazen argued that the FDA approval of TransEnterix's Senhance Surgical Robotic System should be viewed far less in the context of a competitive threat to Intuitive Surgical's da Vinci and more of another sign that the FDA has "eased its bar" for approval. The TransEnterix Senhance system is "at least currently not in the same league as da Vinci," Hazan told investors in a research note titled "Intuitive's First US Competitor Arrives, Sort Of." He admitted, however, that Intuitive is increasingly likely to see new competition, from Medtronic (MDT) first and then Johnson & Johnson's (JNJ) joint venture "much later," on time or earlier than expected. Hazan still expects Intuitive to dominate, however, and kept a Buy rating on the shares. The stock sold off 3% in after-hours trading on the Friday following TransEnterix's announcement. DEMOGRAPHICS: Baby Boomers and Millenials are aging and with that Intuitive Surgical should benefit from an increased need for procedures including radical prostatectomies for Baby Boomer males diagnosed with prostate cancer. Hysterectomy is a common surgical procedure that employs the company's da Vinci machine and with the aging of millennial women, Intuitive stands to benefit.

    ISRG;TRXC;MDT;JNJ10/18 14:30 EDT

    Johnson & Johnson price target raised to $165 from $145 at Argus


    Argus analyst David Toung raises his price target on Johnson & Johnson to $165 and kept his Buy rating following Q3 results. Toung says the top-line growth was driven by oncology and immunology drugs, products gained through the Actelion acquisition, and improved performance in the Consumer segment. The analyst is also positive on the company's strategy of boosting growth through acquisitions and shedding of slower-growth businesses.

    JNJ10/18 08:59 EDT

    Johnson & Johnson price target raised to $155 from $147 at Cowen


    Cowen analyst Joshua Jennings raised his price target on Johnson & Johnson to $155 from $147 following solid Q3 results. The analyst cited the reacceleration of the Pharma group and improvements in the Medical Devices and Consumer units, which he believes will drive sustainable revenue growth. Jennings reiterated his Outperform rating on Johnson & Johnson shares.

    JNJ10/18 08:21 EDT

    Johnson & Johnson price target $155 from $149 at Wells Fargo


    Wells Fargo analyst Lawrence Biegelsen raised his price target for Johnson & Johnson to $155 from $149 after the company reported "strong" Q3 results, driven by top-line acceleration, and raised EPS guidance for the full year. The analyst reiterates an Outperform rating on the shares.

    JNJ10/18 08:10 EDT

    Trovagene's PLK1 inhibitor shows synergy with Johnson & Johnson's Zytiga


    Trovagene (TROV) announced 'positive' data from preclinical research demonstrating synergy of PCM-075, its oral, highly-selective Polo-like Kinase 1 Inhibitor, in combination with abiraterone - Johnson & Johnson's (JNJ) Zytiga. Abiraterone is indicated for the treatment of mCRPC in combination with prednisone. This research was performed in collaboration with a major cancer research institution.

    TROV;JNJ10/18 08:08 EDT

    Johnson & Johnson price target raised to $152 from $145 at BMO Capital


    BMO Capital analyst Joanne Wuensch raised her price target on Johnson & Johnson to $152 following a Q3 earnings beat attributed to a strong uptake of recent pharmaceutical launches, FX tailwinds, and gains from divested assets. Wuensch notes there is still room for a turnaround in Medical Devices and Consumer segments, but adds that progress in those franchises is a positive sign, maintaining her Outperform rating.

    JNJ10/18 08:07 EDT

    Johnson & Johnson price target raised to $165 from $150 at Leerink


    Leerink analyst Danielle Antalffy raised her price target for Johnson & Johnson to $165 from $150 saying the company delivered a "surprisingly strong" quarter in which the Pharma business regained momentum, consumer continued to recover, and Medical Devices managed through not only normal summer seasonality but also hurricane-related headwinds to deliver basically stable procedure volume trends. The analyst reiterates an Outperform rating on the shares.

    JNJ10/18 07:09 EDT

    On The Fly: Top stock stories for Tuesday


    Stocks opened little changed but better than expected earnings from Dow components UnitedHealth (UNH) and Johnson & Johnson (JNJ) helped the blue chip index gain some momentum. The Dow pushed past the 23,000 level for the first time during the session, but closed right below that round number milestone. ECONOMIC EVENTS: In the U.S., industrial production rose 0.3% in September, with capacity at 76.0%. The NAHB housing market index bounced 4 points to a reading of 68. The trade price report beat estimates with big September headline gains of 0.7% for imports and 0.8% for exports. In Europe, the final Eurozone CPI figures for September were inline with the flash readings while Germany's ZEW current situation and expectations readings came in a bit short of expectations. COMPANY NEWS: Netflix (NFLX) reported the addition of 5.3M subscribers in Q3, topping consensus expectations, and its guidance for Q4 also came in slightly above forecasts. However, expectations were elevated heading into the report and the stock responded to the quarterly update with a 1.6% decline... UnitedHealth was the clear winner among the three Dow members that reported this morning, rising 5.6% after its "beat and raise." Johnson & Johnson, which also raised its guidance, gained 3.5% while Goldman Sachs (GS) fell 2.5% despite posting earnings and revenues that topped consensus... In addition to Goldman, big bank peer Morgan Stanley (MS) reported this morning and also posted better than expected top and bottom-line results. Unlike Goldman, the stock advanced 0.3% after the report... Meanwhile, the Hill reported that Republican Senator Lamar Alexander said that he and Democratic Senator Patty Murray have reached a bipartisan deal to extend key Affordable Care Act payments to insurers for two years. The news follows an announcement last week by President Trump that he was cutting off such payments. Shares of a number of health insurance companies as well as shares of hospital operators rose following the news. MAJOR MOVERS: Among the notable gainers was Harley-Davidson (HOG), rising 2% after reporting Q3 earnings. Also higher was Ionis Pharmaceuticals (IONS), which gained over 4% after Morgan Stanley said its survey predicts U.S sales of the spinal muscular atrophy drug Spinraza that are ahead of the consensus view. Freeport McMoran (FCX) was among the noteworthy losers, sliding 2% after Deutsche Bank downgraded the stock to Sell. Also lower was Impax (IPXL), which slipped more than 3% after the company announced an agreement for an all-stock deal to combine with Amneal Pharmaceuticals. INDEXES: The Dow rose 40.48, or 0.18%, to 22,997.44, the Nasdaq dipped 0.35, or 0.01%, to 6,623.66, and the S&P 500 added 1.72, or 0.07%, to 2,559.36.

    NFLX;UNH;JNJ;GS;MS;AET;ANTM;CNC;CI;HUM;MOH;WCG;CYH;HCA;LPNT;THC;UHS;HOG;IONS;FCX;IPXL10/17 16:15 EDT

    Appeals court throws out $72M verdict against J&J, St. Louis Post-Dispatch says


    The appeals court of Missouri's Eastern District threw out a $72M jury verdict against Johnson & Johnson by a woman who had claimed that her longtime use of the company's talcum powder contributed to ovarian cancer, reported the St. Louis Post-Dispatch. The prior decision in February 2016 was the first verdict in which a U.S. jury awarded damages over claims that talc powder contributed to cancer and was the first of four multimillion dollar verdicts against J&J, the report noted. [Reference Link]:Link

    JNJ10/17 12:20 EDT

    J&J gets first St. Louis talc-cancer verdict reversed, Bloomberg says

    JNJ10/17 12:03 EDT

    On The Fly: Top stock stories at midday


    Stocks have mostly drifted since the open and the major averages are little changed near noon. Earnings season got off to a quick start with three Dow components reporting this morning and all of them beat Wall Street estimates. The post-earnings strength in UnitedHealth (UNH) and Johnson & Johnson (JNJ) have helped the Dow surpass 23,000 for the first time in its history, though the blue chip index has slid back under that round-number milestone after crossing above it briefly. ECONOMIC EVENTS: In the U.S., industrial production rose 0.3% in September, with capacity at 76.0%. The NAHB housing market index bounced 4 points to a reading of 68. The trade price report beat estimates with big September headline gains of 0.7% for imports and 0.8% for exports. In Europe, the final Eurozone CPI figures for September were inline with the flash readings while Germany's ZEW current situation and expectations readings came in a bit short of expectations. COMPANY NEWS: Shares of Netflix (NFLX) have declined 2% in early trading after the company's addition of 5.3M subscribers in Q3 topped consensus expectations and its guidance for Q4 also came in slightly above forecasts. However, the stock's strength heading into the earnings report and recent bullish analyst notes indicate that expectations were already elevated... Three Dow members reported this morning, with UnitedHealth the clear winner, rising 5% after its "beat and raise" report. Johnson & Johnson, which also raised its guidance, is up over 2% while Goldman Sachs (GS) is down over 1.5% despite posting earnings and revenues that topped the consensus forecast... In addition to Goldman, big bank peer Morgan Stanley (MS) reported this morning and also posted better than expected top and bottom-line results. Unlike Goldman, the stock has advanced fractionally following the report. MAJOR MOVERS: Among the notable gainers was Harley-Davidson (HOG), rising 2.5% after reporting Q3 earnings. Also higher was Ionis Pharmaceuticals (IONS), which is up 4% after Morgan Stanley said its survey predicts U.S sales of the spinal muscular atrophy drug Spinraza that are 10%-25% ahead of the consensus forecast. Freeport McMoran (FCX) was among the noteworthy losers, sliding 3% after Deutsche Bank analyst Chris Terry downgraded the stock to Sell citing an unfavorable risk/reward profile due to valuation and continued uncertainty at its Grasberg mine. Also lower was Impax (IPXL), which is down 10% after the company announced an agreement for a business combination in an all-stock transaction with Amneal Pharmaceuticals. INDEXES: Near midday, the Dow was up 23.20, or 0.1%, to 22,980.16, the Nasdaq was down 2.75, or 0.04%, to 6,621.26, and the S&P 500 was down 1.42, or 0.06%, to 2,556.22.

    NFLX;UNH;JNJ;MS;GS;HOG;FCX;IONS;IPXL10/17 12:03 EDT

    On The Fly: Pre-market Movers


    UP AFTER EARNINGS: Morgan Stanley (MS), up 1.7%... Johnson & Johnson (JNJ), up just under 1%... UnitedHealth (UNH), up 2.3%... Goldman Sachs (GS), up 1.4%... Comerica (CMA), up 2.5%... W.W. Grainger (GWW), up 2.8%... Tile Shop (TTS), up 5.3%... Omnicom (OMC), up 2.8%. ALSO HIGHER: Neothetics (NEOT), up 73.3% after entering an all-stock merger with Evofem Biosciences... Airbus (EADSY), up 2.9% after acquiring a majority stake in C Series Aircraft Limited Partnership with Bombardier (BDRBF). DOWN AFTER EARNINGS: Harley-Davidson (HOG), down 3.8%... CSX (CSX), down 1.7%... Netflix (NFLX), down 1%. ALSO LOWER: Boeing (BA), down 1.6% following the Airbus/Bombardier partnership announcement... Scana (SCG), down 1.9% after reporting that they were served with a document subpoena issued by the staff of the Securities and Exchange Commission in connection with an investigation they are conducting relating to the new nuclear project at V. C. Summer Nuclear Station.

    MS;JNJ;UNH;GS;CMA;GWW;TTS;OMC;NEOT;EADSY;HOG;CSX;NFLX;BA;SCG10/17 09:22 EDT

    Johnson & Johnson backs FY17 revenue view $75.9B-$76.2B, consensus $75.83


    Guidance in constant currency.

    JNJ10/17 08:59 EDT

    Johnson & Johnson says not assuming any tax reform in FY17 guidance

    JNJ10/17 08:57 EDT

    Johnson & Johnson says Puerto Rico hurricane had limited impact on company


    Says impact was limited to some loss of surgery days. Says does not expect material impact from hurricane. Says has resumed exporting products from Puerto Rico.

    JNJ10/17 08:51 EDT

    Johnson & Johnson says discontinued talacotuzumab after P3 data study data

    JNJ10/17 08:49 EDT

    Johnson & Johnson says still studying sirukumab in depressive disorder

    JNJ10/17 08:46 EDT

    Johnson & Johnson says 'very pleased' with strong Q3 results


    Says sales performance was most pronounced in pharmaceutical segment. Comments from Q3 earnings conference call.

    JNJ10/17 08:36 EDT

    Johnson & Johnson up 2% after reporting Q3 results, raising FY17 adj. EPS view

    JNJ10/17 06:46 EDT

    Johnson & Johnson will not pursue global approvals of sirukumab


    Johnson & Johnson has made a decision not to pursue global approvals of sirukumab for the treatment of moderately to severely active rheumatoid arthritis. In addition, the clinical trial for talacotuzumab, an investigational compound being studied in patients with acute myeloid leukemia, has been discontinued.

    JNJ10/17 06:46 EDT

    Johnson & Johnson raises FY17 adj. EPS view to $7.25-$7.30 from $7.12-$7.22


    Consensus $7.18.

    JNJ10/17 06:44 EDT

    Johnson & Johnson reports Q3 adj. EPS $1.90, consensus $1.80


    Reports Q3 revenue $19.7B, consensus $19.28B.

    JNJ10/17 06:42 EDT

    Notable companies reporting before tomorrow's open


    Notable companies reporting before tomorrow's open, with earnings consensus, include Johnson & Johnson (JNJ), consensus $1.80... UnitedHealth (UNH), consensus $2.56... Goldman Sachs (GS), consensus $4.17... Morgan Stanley (MS), consensus 81c... CSX (CSX), consensus 51c... Progressive (PGR), consensus 35c... Comerica (CMA), consensus $1.19... W.W. Grainger (GWW), consensus $2.56... Harley-Davidson (HOG), consensus 40c... Synovus Financial (SNV), consensus 65c... Tile Shop (TTS), consensus 5c.

    JNJ;UNH;GS;MS;CSX;PGR;CMA;GWW;HOG;SNV;TTS;UNH;GS;MS;CSX;PGR;CMA;GWW;HOG;SNV;TTS10/16 13:13 EDT

    Technical Earnings Preview: Johnson & Johnson near breakout before earnings


    On a 1-year daily chart, the current price range in place since June is bound largely between $130 and $136. Price is currently near the top of the range. If the news is a strong positive, a move above $136 and above the life high at $137.52 could open up a run to the $140-$142 area, in line with the technical upside range target. If the news is a negative surprise, the following support levels could become downside objectives: $133.48, $131.15, and the range low at $130. If the low of the range were taken out it would be a major technical negative. Next support below would be at $128.45.

    JNJ10/16 12:58 EDT

    Trump calls prescription drug prices 'out of control,' CBS reports


    CBS News White House Correspondent Mark Knoller reported that in remarks to the Cabinet, President Trump said that "prescription drug prices are out of control." "Drug companies quite frankly are getting away with murder," added Trump, according to Knoller. Some of the largest publicly traded pharmaceutical companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

    BMY;MRK;GSK;LLY;NVS;PFE;AZN;RHHBY;SNY;JNJ10/16 11:57 EDT

    Jefferies ups price target on top global pick AbbVie to $115


    Jefferies analyst Jeffrey Holford keeps AbbVie (ABBV) as his top global Pharmaceuticals pick for October, followed by Roche (RHHBY), Novartis (NVS), Bayer (BAYRY), Johnson & Johnson (JNJ), Eli Lilly (LLY) and GlaxoSmithKline (GSK). The analyst raised his price target for AbbVie shares to $115 from $107 and keeps a Buy rating on the name. Among his other target changes include bumping Eli Lilly's to $100 from $96.

    ABBV;RHHBY;NVS;BAYRY;JNJ;LLY;GSK10/16 07:21 EDT

    TransEnterix not 'in the same league' as Intuitive Surgical, says Citi


    Citi analyst Amit Hazan believes Friday's FDA approval of TransEnterix's (TRXC) Senhance Surgical Robotic System should be viewed far less in the context of a competitive threat to Intuitive Surgical's (ISRG) da Vinci and more of another sign that the FDA has "eased its bar" for approval. The TransEnterix Senhance system is "at least currently not in the same league as da Vinci," Hazan tells investors in a research note titled "Intuitive's First US Competitor Arrives, Sort Of." He admits, however, that Intuitive is increasingly likely to see new competition, from Medtronic (MDT) first and then Johnson & Johnson's (JNJ) joint venture "much later," on time or earlier than expected. Hazan still expects Intuitive to dominate, however, and keeps a Buy rating on the shares. The stock sold off 3% in after-hours trading on Friday following TransEnterix's announcement.

    ISRG;TRXC;MDT;JNJ10/16 05:19 EDT

    CHMP issues positive opinion to broaded indication for Janssen's Zytiga


    Janssen-Cilag International announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended broadening the existing marketing authorisation for ZYTIGA plus prednisone / prednisolone to include an earlier stage of prostate cancer than its current indications. If approved by the European Commission, abiraterone acetate plus prednisone / prednisolone in combination with androgen deprivation therapy can be used for the treatment of adult men with newly diagnosed high-risk metastatic hormone-sensitive prostate cancer. The CHMP recommendation is based on data from the multinational, multicentre, randomised, double-blind, placebo-controlled Phase 3 study, LATITUDE. The trial was designed to determine if newly diagnosed patients with mHNPC who have high-risk prognostic factors benefit from the addition of abiraterone acetate and prednisone to androgen deprivation therapy vs placebos and ADT. In the LATITUDE study, the safety profile of ADT in combination with abiraterone acetate plus prednisone was consistent with prior studies in patients with metastatic castration-resistant prostate cancer. Most common adverse events were elevated incidences of mineralocorticoid-related hypertension and hypokalemia in the ADT in combination with abiraterone acetate plus prednisone arm compared with ADT and placebos. The observed degrees of hypertension and hypokalemia were both medically manageable with antihypertensive medications and potassium supplements as needed, only rarely required treatment discontinuation, and seldom led to serious consequences. The CHMP's Positive Opinion will now be reviewed by the European Commission, which has the authority to grant approval of the new indication.

    JNJ10/13 07:51 EDT

Data At A Glance (Annual)


  TTM 2017201620152014
Revenue (Millions) $74,361$56,255$71,890$70,074$74,331
Cost of Revenue Expense (Millions) $21,742$5,386$21,685$21,536$22,746
Cost of Revenue Expense (Millions) $21,742$5,386$21,685$21,536$22,746
Current Assets (Millions) $63,347$63,347$65,032$60,210$59,311
Current Debt (Millions) $5,355$5,355$4,684$7,004$3,638
Current Liabilities (Millions) $25,119$25,119$26,287$27,747$25,085
Current Liabilities (Millions) $25,119$25,119$26,287$27,747$25,085
Customer Revenue (Millions) $74,361$56,255$71,890$70,074$74,331
Deferred Taxes (Millions) -$0-$0-$556-$0-$0
Deferred Taxes (Millions) -$0-$0-$556-$0-$0
EBITDA (Millions) $24,629$6,691$24,283$22,172$24,991
EBITDA (Millions) $24,629$6,691$24,283$22,172$24,991
Financing Cash Flow (Millions) -$8,523-$150-$8,551-$10,846-$12,260
Financing Cash Flow (Millions) -$8,523-$150-$8,551-$10,846-$12,260
Free Cash Flow (Millions) $16,770$2,353$15,541$15,816$14,757
Free Cash Flow (Millions) $16,770$2,353$15,541$15,816$14,757
Goodwill (Millions) $24,844$24,844$22,805$21,629$21,832
Gross Profit (Millions) $12,748$12,748$12,590$12,138$12,401
Interest Expense (Millions) $770$204$726$283$533
Interest Expense (Millions) $770$204$726$283$533
Investing Cash Flow (Millions) -$4,160-$936-$4,761-$7,735-$12,305
Investing Cash Flow (Millions) -$4,160-$936-$4,761-$7,735-$12,305
Net Income (Millions) $15,827$12,013$16,375$15,409$16,323
Net Interest Income (Millions) -$0-$0-$0-$0-$0
Net Interest Income (Millions) -$0-$0-$0-$0-$0
Operating Income (Millions) $21,267$5,583$21,136$18,065$20,959
Operating Income (Millions) $21,267$5,583$21,136$18,065$20,959
Research & Development Expense (Millions) $9,142$2,060$9,095$9,046$8,494
Sales to Customers Revenue (Millions) $74,361$56,255$71,890$70,074$74,331
Selling, General & Administrative Expense (Millions) $19,994$4,737$19,945$21,203$21,954
Selling, General & Administrative Expense (Millions) $19,994$4,737$19,945$21,203$21,954
Selling, Marketing & Administrative Expense (Millions) $20,704$15,395$19,945$21,203$21,954
Share Count (Millions) 2,6952,6952,7072,7552,783
Share Count (Millions) 2,6952,6952,7072,7552,783
Total Assets (Millions) $144,918$144,918$141,208$133,411$131,119
Total Assets (Millions) $144,918$144,918$141,208$133,411$131,119
Total Debt (Millions) $32,370$32,370$27,126$19,861$18,760
Total Debt (Millions) $32,370$32,370$27,126$19,861$18,760
Total Equity (Millions) $70,341$70,341$70,418$71,150$69,752
Total Equity (Millions) $70,341$70,341$70,418$71,150$69,752
Total Liabilities (Millions) $74,577$74,577$70,790$62,261$61,367
Total Liabilities (Millions) $74,577$74,577$70,790$62,261$61,367
Asia-Pacific & Africa Customer Revenue (Millions) $13,044$9,941$12,575$12,347$13,442
Europe Customer Revenue (Millions) $16,399$12,398$15,925$15,995$18,947
International Advanced Revenue (Millions) $2,058$1,543$1,993$1,845--
International Babycare Revenue (Millions) $1,470$1,100$1,400$1,629$1,832
International Beauty Care Revenue (Millions) $1,834$1,351$1,762$461--
International Cardiovascular Revenue (Millions) $981$743$901$1,105$1,346
International Cardiovascular / Metabolism Revenue (Millions) $1,490$1,152$1,541$1,659$1,977
International Concerta & Methylphenidate Revenue (Millions) $405$304$395$387$447
International Consumer Revenue (Millions) $7,921$5,876$7,887$8,285$9,400
International Contact Lenses / Other Revenue (Millions) $1,822$1,404$1,715----
International Customer Revenue (Millions) $35,430$26,861$34,079$34,387$39,549
International Darzalex Revenue (Millions) $841$641$200----
International Diabetes Care Revenue (Millions) $1,014$743$1,050$1,095$1,278
International Diagnostics Revenue (Millions) $39$1$66$86$506
International Edurant Revenue (Millions) $629$478$521$369$341
International General Revenue (Millions) $2,704$2,017$2,693$2,780--
International Hips Revenue (Millions) $560$418$563$408--
International Imbruvica Revenue (Millions) $937$749$638$314--
International Immunology Revenue (Millions) $3,293$2,514$3,122$2,760$3,082
International Infectious Diseases Revenue (Millions) $1,741$1,334$1,747$2,121$2,487
International Invega Sustenna, Xeplion & Trinza Revenue (Millions) $947$722$871$745$763
International INVOKANA / INVOKAMET Revenue (Millions) $158$121$134$70$14
International Knees Revenue (Millions) $572$424$581$430--
International Medical Devices Revenue (Millions) $13,402$10,108$12,853$13,005$15,268
International Neuroscience Revenue (Millions) $3,370$2,531$3,457$3,409$4,035
International Oncology Revenue (Millions) $3,879$3,012$3,472$3,148$3,300
International OPSUMIT Revenue (Millions) $130$130------
International Oral Care Revenue (Millions) $912$678$920$951$1,047
International Orthopaedics Revenue (Millions) $3,792$2,827$3,813$3,882$4,478
International Other / Cardiovascular / Metabolism Revenue (Millions) $1,030$802$1,069$1,213$1,445
International Other Immunology Revenue (Millions) $27$20$25$39$66
International Other Infectious Diseases Revenue (Millions) $416$329$513$558$881
International Other Neuroscience Revenue (Millions) $1,657$1,259$1,828$1,521$1,782
International Other Oncology Revenue (Millions) $354$268$390$340$416
International Other Pulmonary Hypertension Revenue (Millions) $41$41------
International Over the Counter Revenue (Millions) $2,332$1,711$2,357$2,408$2,749
International Pharmaceutical Customer Revenue (Millions) $14,107$10,877$13,339$13,097$14,881
International PREZISTA / PREZCOBIX / REZOLSTA Revenue (Millions) $691$527$708$746$901
International PROCRIT / EPREX Revenue (Millions) $302$229$338$376$523
International Pulmonary Hypertension Revenue (Millions) $334$334------
International Remicade Revenue (Millions) $1,291$949$1,342$1,326$1,635
International Risperdal Consta Revenue (Millions) $453$335$512$561$763
International Simponi/Simponi Aria Revenue (Millions) $825$642$816$598$643
International Specialty Revenue (Millions) $594$432$584$601--
International Spine & Other Revenue (Millions) $1,632$1,217$1,645$1,251--
International Stelara Revenue (Millions) $1,150$903$969$797$738
International Surgery Revenue (Millions) $5,356$3,992$5,270$5,226--
International Surgical Revenue (Millions) $398$398------
International TRACLEER Revenue (Millions) $151$151------
International Trauma Revenue (Millions) $1,028$768$1,024$774--
International UPTRAVI Revenue (Millions) $12$12------
International Velcade Revenue (Millions) $1,117$843$1,224$1,333$1,618
International Vision Care Revenue (Millions) $2,258$1,802$1,753$1,611--
International Womens Health Revenue (Millions) $1,040$779$1,038$1,174$1,232
International Wound Care Revenue (Millions) $333$257$348$420$596
International Zytiga Revenue (Millions) $1,194$924$1,171$1,161$1,266
US Advanced Revenue (Millions) $1,583$1,190$1,524$1,430--
US Baby Care Revenue (Millions) $449$326$442$444$407
US Beauty Care Revenue (Millions) $2,319$1,739$2,135$442--
US Cardiovascular Revenue (Millions) $1,032$785$948$931$862
US Cardiovascular / Metabolism Revenue (Millions) $4,734$3,469$4,855$4,759$3,600
US Concerta & Methylphenidate Revenue (Millions) $387$284$468$434$152
US Consumer Revenue (Millions) $5,573$4,186$5,420$5,222$5,096
US Contact Lenses / Other Revenue (Millions) $1,115$832$1,050----
US Customer Revenue (Millions) $38,931$29,394$37,811$35,687$34,782
US Darzalex Revenue (Millions) $794$643$151----
US Diabetes Care Revenue (Millions) $673$482$739$833$864
US Diagnostics Revenue (Millions) -$0-$0-$0-$0$456
US Edurant Revenue (Millions) $58$44$52$41$25
US General Revenue (Millions) $1,691$1,276$1,669$1,702--
US Hips Revenue (Millions) $820$612$798$591--
US Imbruvica Revenue (Millions) $780$622$613$375--
US Immunology Revenue (Millions) $8,801$6,644$8,846$7,642$7,111
US Invega Sustenna, Xeplion & Trinza Revenue (Millions) $1,514$1,154$1,343$1,085$825
US INVOKANA / INVOKAMET Revenue (Millions) $1,057$723$1,273$1,238$555
US Knees Revenue (Millions) $949$702$943$690--
US Medical Devices Revenue (Millions) $12,658$9,510$12,266$12,132$12,254
US Neuroscience Revenue (Millions) $2,562$1,931$2,628$2,850$2,452
US Oncology Revenue (Millions) $2,802$2,207$2,335$1,587$1,157
US OPSUMIT Revenue (Millions) $174$174------
US Oral Care Revenue (Millions) $623$460$648$629$600
US Orthopaedics Revenue (Millions) $5,514$4,092$5,521$5,380$5,197
US Other / Cardiovascular / Metabolism Revenue (Millions) $592$445$527$961$987
US Other Immunology Revenue (Millions) $16$16------
US Other Infectious Diseases Revenue (Millions) $204$152$261$257$215
US Other Neuroscience Revenue (Millions) $296$220$390$583$688
US Other Oncology Revenue (Millions) $153$116$381$82$186
US Other Pulmonary Hypertension Revenue (Millions) $47$47------
US Over the Counter Revenue (Millions) $1,728$1,310$1,633$1,540$1,357
US Pharmaceutical Customer Revenue (Millions) $20,700$15,698$20,125$18,693$17,432
US PREZISTA / PREZCOBIX / REZOLSTA Revenue (Millions) $1,107$824$1,143$1,064$930
US PROCRIT / EPREX Revenue (Millions) $697$511$767$692$715
US Pulmonary Hypertension Revenue (Millions) $427$427------
US Remicade Revenue (Millions) $4,625$3,452$4,694$4,453$4,155
US Risperdal Consta Revenue (Millions) $365$273$381$409$427
US Simponi/Simponi Aria Revenue (Millions) $944$701$959$730$544
US Specialty Revenue (Millions) $758$543$833$859--
US Spine & Other Revenue (Millions) $2,172$1,599$2,235$1,692--
US Stelara Revenue (Millions) $2,659$2,027$2,263$1,677$1,334
US Surgery Revenue (Millions) $4,032$3,009$4,026$3,911--
US Surgical Revenue (Millions) $310$310------
US TRACLEER Revenue (Millions) $85$85------
US Trauma Revenue (Millions) $1,573$1,179$1,545$1,098--
US UPTRAVI Revenue (Millions) $121$121------
US Vision Care Revenue (Millions) $1,407$1,142$1,032$997--
US Womens Health Revenue (Millions) $12$9$19$26$49
US Wound Care Revenue (Millions) $442$342$522$723$848
US XARELTO Revenue (Millions) $2,388$1,790$2,288$1,868$1,522
US Zytiga Revenue (Millions) $1,075$826$1,089$1,070$971
US Exports Remicade Revenue (Millions) $557$448$838$782$1,078
Western Hemisphere Customer Revenue (Millions) $5,987$4,522$5,734$6,045$7,160
Worldwide Advanced Revenue (Millions) $3,641$2,733$3,517$3,275--
Worldwide Babycare Revenue (Millions) $2,010$1,426$2,001$2,044$2,239
Worldwide Beauty Care Revenue (Millions) $4,153$3,090$3,897$903--
Worldwide Cardiovascular Revenue (Millions) $2,013$1,528$1,849$2,036$2,208
Worldwide Cardiovascular / Metabolism Revenue (Millions) $6,224$4,621$6,396$6,418$5,577
Worldwide Concerta & Methylphenidate Revenue (Millions) $792$588$863$821$599
Worldwide Consumer Revenue (Millions) $13,494$10,062$13,307$13,507$14,496
Worldwide Contact Lenses / Other Revenue (Millions) $2,937$2,236$2,765----
Worldwide Darzalex Revenue (Millions) $1,071$871$200----
Worldwide Diabetes Care Revenue (Millions) $1,687$1,225$1,789$1,928$2,142
Worldwide Diagnostics Revenue (Millions) $39$1$66$86$962
Worldwide Edurant Revenue (Millions) $687$522$573$410$365
Worldwide General Revenue (Millions) $4,395$3,293$4,362$4,482--
Worldwide Hips Revenue (Millions) $1,380$1,030$1,361$999--
Worldwide Imbruvica Revenue (Millions) $1,717$1,371$1,251$689--
Worldwide Immunology Revenue (Millions) $12,094$9,158$11,484$10,402$10,193
Worldwide Infectous Diseases Revenue (Millions) $3,115$2,354$3,208$3,656$5,599
Worldwide Invega Sustenna, Xeplion & Trinza Revenue (Millions) $2,461$1,876$2,214$1,830$1,588
Worldwide INVOKANA / INVOKAMET Revenue (Millions) $1,215$844$1,407$1,308$569
Worldwide Knees Revenue (Millions) $1,028$880$581$430--
Worldwide Medical Devices Revenue (Millions) $26,060$19,618$25,119$25,137$27,522
Worldwide Neuroscience Revenue (Millions) $5,932$4,462$6,085$6,259$6,487
Worldwide Oncology Revenue (Millions) $6,681$5,219$5,807$4,695$4,457
Worldwide OPSUMIT Revenue (Millions) $304$304------
Worldwide Oral Care Revenue (Millions) $1,535$1,138$1,568$1,580$1,647
Worldwide Orthopaedics Revenue (Millions) $9,306$6,919$9,334$9,262$9,675
Worldwide Other / Cardiovascular / Metabolism Revenue (Millions) $1,622$1,247$1,596$2,174$2,432
Worldwide Other Immunology Revenue (Millions) $43$36$25$39$66
Worldwide Other Infectious Diseases Revenue (Millions) $620$481$774$815$1,096
Worldwide Other Neuroscience Revenue (Millions) $1,805$1,390$1,890$2,065$2,470
Worldwide Other Oncology Revenue (Millions) $507$384$771$422$602
Worldwide Other Pulmonary Hypertension Revenue (Millions) $88$88------
Worldwide Over the Counter Revenue (Millions) $4,007$3,021$3,977$3,975$4,106
Worldwide Pharmaceutical Customer Revenue (Millions) $34,807$26,575$33,464$31,430$32,313
Worldwide PREZISTA / PREZCOBIX / REZOLSTA Revenue (Millions) $1,798$1,351$1,851$1,810$1,831
Worldwide PROCRIT / EPREX Revenue (Millions) $999$740$1,105$1,068$1,238
Worldwide Pulmonary Hypertension Revenue (Millions) $761$761------
Worldwide Remicade Revenue (Millions) $6,473$4,849$6,966$6,561$6,868
Worldwide Risperdal Consta Revenue (Millions) $818$608$893$970$1,190
Worldwide Simponi/Simponi Aria Revenue (Millions) $1,769$1,343$1,745$1,328$1,187
Worldwide Skincare Revenue (Millions) $3,897--$3,897$3,531$3,758
Worldwide Specialty Revenue (Millions) $1,352$975$1,417$1,460--
Worldwide Spine & Other Revenue (Millions) $3,804$2,816$3,880$2,943--
Worldwide Stelara Revenue (Millions) $3,809$2,930$3,232$2,474$2,072
Worldwide Surgery Revenue (Millions) $9,388$7,001$9,296$9,217--
Worldwide Surgical Revenue (Millions) $708$708------
Worldwide TRACLEER Revenue (Millions) $236$236------
Worldwide Trauma Revenue (Millions) $2,601$1,947$2,569$1,872--
Worldwide UPTRAVI Revenue (Millions) $133$133------
Worldwide Velcade Revenue (Millions) $1,117$843$1,224$1,333$1,618
Worldwide Vision Care Revenue (Millions) $3,665$2,944$2,785$2,608--
Worldwide Womens Health Revenue (Millions) $1,052$788$1,067$1,200$1,302
Worldwide Wound Care/Other Revenue (Millions) $673$599$797$1,177$1,444
Worldwide XARELTO Revenue (Millions) $2,388$1,790$2,288$1,868$1,522
Worldwide Zytiga Revenue (Millions) $2,269$1,750$2,290$2,231$2,237